Immune checkpoint inhibitors have shown to be very effective when treating lung cancer. Nivolumab, a programmed death-1 (PD-1) inhibitor has been approved for the treatment of metastatic non-squamous and squamous NSCLC. Immunotherapy with checkpoint inhibitors are associated with toxicities defined as immune-related adverse events (irAEs). The most common irAEs are rash, colitis, hepatitis, pneumonitis, and endocrinopathies. Although any organ system can be affected, other rare irAEs can occur and affect the bone marrow, pancreas, and the neurologic and cardiac systems. Pericardial effusion induced by immunotherapy is uncommon and has been described only in a few case reports. Immune-related adverse events usually develop within the first weeks to months after treatment initiation. This is a case report of a 52-year-old male patient with metastatic squamous-cell lung cancer who had a massive pericardial effusion secondary to treatment with nivolumab as second line treatment. During his hospital stay, the patient underwent pericardiocentesis and treatment with corticosteroids. A CT scan after these treatments revealed complete tumor response and minimal pericardial effusion. Nivolumab was definitively ceased. The patient continues to show complete response for 16 months. In general, Nivolumab is well-tolerated and has an excellent safety profile. However, it is important to be aware of life-threatening immune-related adverse events, particularly cardiac toxicity. Consensus guidelines regarding the treatment of the most common irAEs have been established. The optimal management of irAEs is based on clinical experience. It's crucial to report new or rare irAEs to conduct prospective trials to evaluate the best treatment strategy.
Introduction
Nivolumab is a fully human IgG4-programmed death 1 (PD-1) inhibitor belonging to a family of drugs known as immune checkpoint inhibitors associated with toxicities defined as immune-related adverse events (irAEs). Immunotherapy with Nivolumab has shown to be effective in the treatment of non-small cell lung cancer (NSCLC).
Immune-related adverse events commonly affect the gastrointestinal tract, skin, endocrine glands, and the liver and less often the central nervous, cardiovascular, pulmonary, musculoskeletal, and hematologic systems [1] . Although the pathophysiology of irAEs is not yet fully known, it is believed to be related to the role that immune checkpoints play in maintaining immunologic homeostasis [2] .
The toxicity profile of checkpoint inhibitors was first described in the studies on ipilimumab, an anti-CTLA-4 antibody used in the treatment of melanoma [3] . Cardiac irAEs are rare, occurring in <1% of patients treated with immune checkpoint inhibitors therapy [4] .
Pericardial effusion has not been often described as a side effect of nivolumab therapy, being the incidence rate with this drug of 0.06 [5] . This is a case report of a 52-year-old male patient with metastatic squamous-cell lung cancer who had a massive pericardial effusion secondary to treatment with nivolumab as second line treatment.
Case Report
In February 2016, a 52-year-old man with a history of smoking was diagnosed with squamous-cell carcinoma (PD-L1 inconclusive) with lung and brain metastases (stage IVB). The patient had no previous history of cardiovascular disease and no previous history of hypertension or rheumatologic disease. CT scan findings showed a 4.7 by 4.0 cm spiculated mass involving and narrowing the basal bronchi and occluding the bronchus of the upper segment and extending to the lingula. It also showed hilar lymph nodes of the upper left, subcarinal, and paratracheal and lymph nodes of the lower right and left, and subaortic (2.2 by 1.8 cm). Two nodes in the upper lingular segment without pleural or pericardial effusion ( Figure 1 ). An MRI the of brain from March 2016 showed multifocal nodular lesions in the following lobes: 1) left frontal, 2) temporal and right parietal, and 3) right occipital and left upper frontal. The patient then underwent a series of cranial irradiation of the central nervous system at 40 Gy, 2 Gy per fraction, which he completed in May 2016 with complete response. He was monitored clinically and by imaging every 3 months. [8] . The most common irAEs are rash, colitis, hepatitis, pneumonitis, and endocrinopathies. Consensus regarding the treatment of these irAEs has been established [5] [9] .
In case reports of myocarditis, T-cell clones infiltrating the myocardium were identical to those present in tumors and skeletal muscle, leading to the speculation that these selective clonal T-cell populations may have reacted against a common, shared antigen of normal myocardium tissue and tumor [10] . Pericarditis and pericardial effusion induced by immunotherapy has been unfrequently described. The first case reports of pericardial effusion was described with ipilimumab in 2015 and 2016 [11] [12] . The pericardial effusion as a side effect of nivolumab was primarily described by Nesfeder et al. (2016) , [13] . They reported a case of non-malignant pericardial effusion that progressed, after initiation of nivolumab, to tamponade physiology. Others five cases of nivolumab causing pericardial effusion were reported in the literature [14] [15] [16] [17] . Cardiac tamponade also occurred in a patient with lung cancer in whom tuberculous pericarditis had developed due to a hypersensitivity-related response 3 months after nivolumab treatment was initiated [18] . As far as I know, this is the seventh case of nivolumab-associated pericardial effusion described in the literature and the case with the largest volume drained (2500 cm 3 ). Immune-related adverse events usually develop within the first weeks to months after treatment initiation but can be present at any time, including after cessation of immune checkpoint blockade therapy [2] .
A recent observational, retrospective, pharmacovigilance study (used VigiBase, WHO's global database of individual case safety reports) identified 31.321 cardiovascular adverse events reported in patients who received immune checkpoint inhibitors [19] . Pericardial diseases in patients with lung cancer treated with anti-PD-1 or anti-PD-L1 antibodies were over-reported (49) [56%] of 87 patients. Cardiovascular irAEs occurred soon after immune checkpoint inhibitors administration with a median time to the onset of pericardial diseases of 30 days (9 -90).
Some studies suggest a possible correlation between tumor regression and the magnitude of autoimmune toxicity, especially toxicities grades 3 and 4. Tumor regression was seen in multiple organs and most objective cancer regressions have been long-lasting [20] [21] . A retrospective study based on landmark and Journal of Cancer Therapy multivariable analyses in patients with advanced or recurrent NSCLC treated with nivolumab in second-line settings or later revealed that irAEs were associated with nivolumab efficacy [22] . In this study, when setting the landmark at 6 weeks, the median progression free survival with irAES was 9.2 months (95% CI 4.4 to NR (not reached)) and 4.8 months without irAEs (95% CI 3.0 to 7.5) (p = 0.04). Median overall survival were with irAEs NR (95% CI 12.3 to NR) and 11.1 months (95% CI 9.6 to NR) (p = 0.01) without irAEs.
In this case report, our patient presented with pericardial effusion and cardiac tamponade 6 weeks after treatment initiation. Pericardiocentesis was performed and steroid treatment was based on established severe pneumonitis treatment [5] . It is important to plan for a gradual withdrawal of corticoids, whose complete withdrawal should take place in at least 30 days. If corticoids are stopped in less than 30 days, the patient may relapse at the same rate as before.
The most commonly used first-line immunosuppressive agent to treat this excessive immunity against normal organs are glucocorticoids followed by additional immunosuppressive agents if glucocorticoids are initially ineffective in more severe cases. The most frequently used immunosuppressive agents are infliximab and, in the case of hepatitis, Mycophenolate mophetil (MMF), followed by Anti-thymocyte globulin (ATG) in steroid-refractory cases [23] [24] .
The prophylactic use of sulfamethoxazole trimethoprim prevents opportunistic infections at a steroid equivalent dose of 1 mg/kg [25] .
A more aggressive medical management, often including high doses of corticosteroids, may be adopted to control and even reverse all autoimmune toxicities [20] . Life-threatening toxicity, including cardiac, pulmonary or neurologic toxicities in particular is an absolute contraindication to restarting treatment with immune checkpoint blockage [2] . A retrospective study evaluated the possibility of retreating patients with advanced NSCLC with checkpoint inhibitors after the occurrence of irAEs. The safety and benefit of retreatment remains unknown. They recommend that patients requiring hospitalization for an initial irAEs and those who have already achieved a complete or partial response before an initial irAEs should not be retreated [26] .
Conclusions
Pericardial effusion as side effect of nivolumab is rare. The management of autoimmune cardiac toxicity requires special consideration due to its potentially lethal nature unless aggressively treated. Most of the toxic effects of immune checkpoints inhibitors are reversible if properly treated and death from irAEs is uncommon.
Multidisciplinary team work is needed to early recognition and unifying management strategies of irAEs in order to optimize the safety of anti-PD-1 and anti-PD-L1 therapy.
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